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Survival Motor Neuron (SMN) 
protein is required for normal 
mouse liver development
Eva Szunyogova1,2, Haiyan Zhou3, Gillian K. Maxwell1, Rachael A. Powis2,4, 
Muntoni Francesco3, Thomas H. Gillingwater2,4 & Simon H. Parson1,2
Spinal Muscular Atrophy (SMA) is caused by mutation or deletion of the survival motor neuron 1 
(SMN1) gene. Decreased levels of, cell-ubiquitous, SMN protein is associated with a range of systemic 
pathologies reported in severe patients. Despite high levels of SMN protein in normal liver, there is 
no comprehensive study of liver pathology in SMA. We describe failed liver development in response 
to reduced SMN levels, in a mouse model of severe SMA. The SMA liver is dark red, small and has: 
iron deposition; immature sinusoids congested with blood; persistent erythropoietic elements and 
increased immature red blood cells; increased and persistent megakaryocytes which release high levels 
of platelets found as clot-like accumulations in the heart. Myelopoiesis in contrast, was unaffected. 
Further analysis revealed significant molecular changes in SMA liver, consistent with the morphological 
findings. Antisense treatment from birth with PMO25, increased lifespan and ameliorated all 
morphological defects in liver by postnatal day 21. Defects in the liver are evident at birth, prior to 
motor system pathology, and impair essential liver function in SMA. Liver is a key recipient of SMA 
therapies, and systemically delivered antisense treatment, completely rescued liver pathology. Liver 
therefore, represents an important therapeutic target in SMA.
Spinal Muscular Atrophy (SMA) is a mainly childhood-onset form of motor neuron disease1,2, caused by a dele-
tion or loss-of-function mutation of the Survival Motor Neuron-1 (SMN1) gene3. The protein product; Survival 
Motor Neuron (SMN) is a cell-ubiquitous, key component of the spliceosome, and deletion is embryonic lethal4. 
However, the activity of the SMN2 copy gene in humans, compensates by generating sufficient full-length protein 
to ensure survival, though the predominate protein produced is truncated due to exon skipping in most organs4. 
The SMN protein was characterised and named according to an apparent, specific vulnerability of motor neurons 
to low levels of the protein4. But, the absolute dependence of all cells on SMN protein has directed us to examine 
non-motor pathologies in SMA, in order to further understand the role of this multi-functional protein during 
development.
Reduced SMN protein levels result in a wide range of systemic pathologies including; lung, heart, vascular 
system5,6 and testis7. These systemic defects must be described and understood before effective therapies can be 
designed. Significantly, there is considerable evidence of circulatory system defects in animal models and SMA 
patients, with reports of defects in heart morphology8–19 and function20–26. In addition, there is a growing body of 
evidence to support a wide range of defects affecting the structural and circulating component of the vascular sys-
tem: capillaries are depleted in muscle and spinal cord27,28, resulting in significant tissue hypoxia28; red and white 
cell counts are altered29, blood clots are present30, anti-coagulation therapy resolves digital necrosis30,31; SMN 
protein is enriched in anuclear platelets32 and platelet numbers are altered by therapeutic interventions in SMA29.
The liver has high levels of SMN protein expression33 and is a significant player in the production of platelets 
by resident megakaryocytes at the early stages of development34, and therefore a likely target for aberrant blood 
cell production. However, pathology in the liver is poorly described in SMA, though several lines of research have 
implicated its involvement: liver has a higher level of SMN expression than spinal cord in adult human tissue33 
and targeted deletion of SMN in embryonic mouse liver results in dramatic atrophy and severe dysfunction, 
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iron overload, failure to regenerate and late embryonic lethality35. Significantly, increasing SMN protein levels in 
neonatal liver by systemic administration of antisense oligonucleotide (AO-10-27), robustly rescues severe SMA 
mice36, and this peripheral restoration of SMN compensates for its deficiency in the CNS and preserves motor 
neurons36.
Given the requirement for SMN protein in liver, and its implication in downstream disease mechanisms, we 
have carried out a detailed morphological, molecular and functional assessment of liver in a mouse model of 
severe SMA. We show delayed development of hepatic plates with an abnormal preservation of foetal morphology 
and cellular processes into the postnatal period. Specifically, erythropoiesis is prolonged, resulting in congestion 
of liver sinusoids with erythrocyte precursor cells and shedding of excessive numbers of platelets into the cir-
culatory system, which aggregate into clot-like accumulations. Corroborative molecular changes are present in 
developmental and erythropoietic pathways, and antisense restoration of SMN from birth, results in full recovery 
of liver morphology. Finally, we uncovered an unexpected SMN2 splicing pattern in control liver, suggesting that 
developmental shifts in splicing may be important in organs other than the testis7.
These findings suggest a key dependence on normal SMN protein levels for liver development and function, 
and that deficiency results in prolonged extramedullary erythropoiesis leading to altered blood composition and 
function. These data further elucidate the functional complexity of the SMN protein.
Results
SMA Liver is Relatively Normal in Form but Has a Distinctive Dark Red Colour. Gross anatomical 
analysis of SMA liver revealed no detectable structural abnormalities. The SMA liver was significantly smaller 
when compared to littermate control (*p < 0.05) however its reduced size was in proportion to reduced body 
weight (ns p > 0.05). The most striking difference between SMA liver and its littermate control was the dark-red 
colouration, which was present at birth (P1) and maintained until a late symptomatic timepoint (P9: Fig. 1A,B).
SMA Liver Shows Developmental Failure. We examined liver function by looking for iron accumula-
tion in SMA liver, as complete loss of SMN results in embryonic iron overload35. Perl’s staining revealed small 
iron deposits at birth (P1) in both control and SMA liver (Fig. 2A). These disappear as development progresses 
in control, and none are present at P5 or P9. However, in SMA liver iron deposition, indicative of defective iron 
homeostasis persists through P5 and P9 (Fig. 2A). Closer inspection also revealed the presence of small numbers 
of disorganised sinusoids and a failure to develop clearly defined sinusoidal spaces between hepatic plates as 
present in control. In addition, the majority of the tissue is dominated by dense clusters of dark red nuclei, charac-
teristic of sites of blood cell production in erythroblastic islands. Finally, the SMA liver appears to have more red 
blood cells (RBC) within the sinusoids, but not in the major blood vessels from P1 to P9.
To further examine these structural defects, we carried out H&E histological analysis of liver. This confirmed 
the presence of poorly developed sinusoids and a relatively immature morphology at all ages examined in SMA 
(Fig. 2B). Active haematopoiesis, indicated by the presence of haematopoietic elements: erythroblastic islands, 
megakaryocytes and granulocytes is present at birth (P1) in both control and SMA liver. As development pro-
ceeds, these haematopoietic elements decrease and eventually disappear, while well-organised and differentiated, 
one to two hepatocytes wide, mature hepatic plates form in the control (Fig. 2B). However, in the SMA liver 
active haematopoiesis is maintained, evident by the high number of haematopoietic elements present (Fig. 2B). 
In addition, wide sinusoids indicating a failure of the liver parenchyma to expand are present at birth (Fig. 2B). 
Hepatocytes remain disorganised and do not mature into hepatic plates in SMA liver (Fig. 2B. Histology indicated 
that some of the RBCs within SMA liver sinusoids appear to be nucleated, which was confirmed upon further 
blood analysis (Fig. 2C), as SMA mice have significantly increased number of normoblasts, immediate precursors 
of RBCs, (*p < 0.05) at P8.
Taken together, the findings of iron accumulation, persistent haematopoietic elements and delayed morpho-
logical maturation, suggest developmental failure in SMA liver.
Erythropoiesis is Elevated and Prolonged in SMA Liver. The SMA liver is dark red, developmentally 
immature and congested with blood. We first confirmed the presence of abnormal quantities of RBC in SMA 
Figure 1. SMA Liver is Relatively Normal in Size with a Distinctive Dark Red Phenotype. (A) Gross 
anatomy of SMA liver harvested from late symptomatic Taiwanese mice. Scale bar, 50 mm. (B) Quantification 
of liver weight of P9 Taiwanese mice. p values were calculated using two-tailed Student’s t-test. Error bars, 
mean ± s.e.m. (n = 3 mice per group).
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Figure 2. Persistent Erythropoietic Elements in SMA Liver Shows Developmental Failure. (A) Representative 
light microscopy of Perl’s staining of livers at birth (P1) and postnatal days 5 (P5) and 9 (P9). Note the presence of iron 
deposits (black arrowheads) in later stages of development in SMA liver. P9 SMA liver appears to lack the organised 
hepatic plate structure as seen in control with predominant erythroblastic islands (dark red nuclei clusters). Green 
arrowheads point to RBCs outside main vessels. Magnified panels at bottom left show iron deposits (blue). Scale 
bar, 50 μ m. Magnified panel scale bar, 10 μ m. (B) Representative light microscopy of H&E-stained micrographs of 
livers. Red arrowheads show nucleated RBC within sinusoid. Yellow arrowheads and magnified panels at top right 
show megakaryocytes. P9 rectangular magnified panel shows nicely formed hepatic plate in control and lack thereof 
in SMA. Scale bar, 50 μ m. Magnified panel scale bar, 10 μ m. (C) White blood cell (WBC) differential showing the 
percentage of normoblasts in control and SMA blood samples obtained from P8 Taiwanese mice. p values were 
calculated using two-tailed Student’s t-test. Error bars, mean ± s.e.m. (n = 4 mice per group).
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liver sinusoids by staining with Ly76 for RBC and RBC precursors (Fig. 3A,B). In control liver, the amount of 
Ly76 positive RBC and precursors is initially low and rapidly decreased as development progressed, resulting in 
the presence of only a few, scattered Ly76-positive cells at P9 (Fig. 3A). SMA liver showed elevated levels at birth 
(P1: non-significant), which were maintained (P5: *p < 0.05) began to fall, but remained 4 times greater than con-
trols (P9: ***p < 0.001) (Fig. 3B). Further analysis, by co-staining with a nuclear marker DAPI, revealed these cells 
to be nucleated and therefore erythrocyte precursor cells (Fig. 3C,D), which were elevated at birth (P1: *p < 0.05) 
remained high at (P5: ***p < 0.001), ultimately decreased (P9: ***p < 0.001) but remained almost 10 times greater 
than in control.
Megakaryocytes Persist and Produce Abnormally High Levels of Platelets in SMA Liver. Our 
histological findings indicated increased numbers of megakaryocytes in the SMA liver, and with the evidence of 
prolonged erythropoiesis, we next sought to determine if megakaryopoiesis was also affected. First, we stained 
sections with CD41, a well-characterised marker for megakaryocytes (Fig. 4A). Megakaryocytes are generally 
sparse, and the low levels present at birth, slowly decreased to near zero in control liver by P9 (Fig. 4A). In SMA 
liver there appear to be more megakaryocytes present at birth, and only a slight decline in numbers through P5 
to P9 (Fig. 4A).
CD41 also identifies platelets, apparent as clumps of much smaller structures, which are easily differentiated 
from the megakaryocytes by size and absence of nuclei (Fig. 4B). These can be used as a surrogate marker for 
megakaryopoiesis and in control liver, platelet numbers were low at birth and P5, falling to almost zero by P9 
(Fig. 4B). The situation was quite different in SMA liver, where increased numbers of platelets was present at birth, 
and maintained through P5 to P9 (Fig. 4B). This confirms abnormal megakaryopoiesis at all developmental stages 
in SMA liver.
Platelets Aggregate into Circulating Clot-like Accumulations in SMA. We were keen to determine 
if this increase in platelet production and retention by liver results in changes in circulating platelets. We therefore 
investigated the heart from the same animals that the liver was obtained to look for any evidence of abnormalities 
in circulating platelets. Initial histological assessment immediately indicated substantial accumulation of blood 
in both ventricles of SMA heart, which was not present in littermate controls (Fig. 5). We co-stained sections of 
Figure 3. Prolonged Active Erythropoiesis in SMA Liver. (A) Representative micrographs labelled with the 
Ly76 marker (green), in sections of liver obtained from Taiwanese mice. Scale bar, 100 μ m. (B) Quantification 
of erythrocytes and their precursors expressed as a percentage of cross-sectional liver area. p values were 
calculated using two-tailed Student’s t-test. Error bars, mean ± s.e.m. (n ≥ 3 mice per group). (C) Representative 
micrographs and their magnified panels co-stained with the Ly76 marker (green) and DAPI (blue), in sections 
of liver obtained from Taiwanese mice. Scale bar, 50 μ m. Magnified panel scale bar, 10 μ m. (D) Quantification of 
erythrocyte precursor cells expressed as a percentage of cross-sectional liver area. p values were calculated using 
two-tailed Student’s t-test. Error bars, mean ± s.e.m. (n ≥ 3 mice per group).
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heart at P5 with CD41 for megakaryocytes and platelets, Ly76 for the RBC lineage and DAPI for nuclei to dif-
ferentiate mature RBC from their nucleated precursors. At P5, large accumulations of mature RBC are present 
in both ventricles, but closer inspection shows those in the right ventricle include significant accumulations of 
platelets (Fig. 5). The combined RBC and platelet aggregates have the appearance of a clot. Interestingly, the blood 
in left ventricle of SMA mice is different, and does not exhibit clot-like appearance (Fig. 5), but is not observed 
in control littermates and suggests gross changes in circulating blood composition and/or cardiac dysfunction. 
These data suggest that the prolonged and abnormal production of platelets and RBC precursors by the liver, leads 
to changes in circulating blood composition and formation of clot-like accumulations.
Myelopoiesis Does Not Appear to Be Affected in SMA Liver. Finally, to investigate if developmental 
failure was a general feature of SMA liver, we stained sections with CD11b, an integrin expressed on the surface of 
myeloid leukocytes, to identify cells of the myelopoiesis lineage, a significant pathway normally also activated in 
haematopoiesis. Our staining revealed no apparent differences in the presence of granulocytes and monocytes in 
control and SMA liver, and a predicted decrease in their levels as development progressed (Fig. 6A). This suggests 
that the generation of white blood cells (myelopoiesis) is not defective in SMA liver. Results from a white blood 
cell (WBC) differential analysis (Fig. 6B) showed no significant differences in the numbers of circulating myeloid 
leukocytes (neutrophils, eosinophils, basophils and monocytes) between SMA and control at late symptomatic 
age (P8).
Figure 4. Megakaryocytes Persist and Produce Abnormally High Levels of Platelets in SMA Liver.  
(A) Representative micrographs of CD41 (green) staining for erythroid lineage and their magnified panels co-
stained with DAPI (blue), showing megakaryocytes in sections of liver from Taiwanese mice. Scale bar, 100 μ m. 
Magnified panel scale bar, 10 μ m. (B) Representative micrographs of CD41 (green) staining showing platelets in 
sections of liver from Taiwanese mice. Scale bar, 50 μ m.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:34635 | DOI: 10.1038/srep34635
These data suggest that developmental failure is not a generalised feature of liver development in SMA, but 
rather specific pathways are selectively targeted by low levels of SMN protein.
Molecular Pathways are Modified in SMA Liver. In order to investigate which pathways were affected 
by low SMN levels, we carried out preliminary molecular analysis by RT-PCR and western blot. Using RT-PCR, 
we show a dramatic reduction in both albumin (Fig. 7A: **p < 0.01) and α-FTP (Fig. 7B: **p < 0.01) mRNA 
expression in SMA liver compared to control at a late symptomatic time point (P11). These results support our 
detailed histological assessment of the liver showing failed development as a key general finding. Importantly, 
these molecules were also identified following liver-specific knockout of SMN35.
We also found an increase in iron accumulation, indicated by histological Perl’s stain (Fig. 2A), in SMA liver. 
Therefore, we next assessed the expression of Ireb-2, which is reduced in SMN-depleted embryonic stem cells38, 
and important in cellular iron homeostasis37. Ireb-2 mRNA expression was also significantly depleted in SMA 
liver (Fig. 7C: **p < 0.01) at a late symptomatic time point (P11).
In addition, SMA liver was dark red in colour and congested with blood. Significantly many of the red blood 
cells were immature, nucleated normoblasts, indicative of ongoing erythropoiesis. Therefore, we next assessed 
erythropoetin (EPO), the master regulator of erythropoiesis39. We found a significant increase in EPO protein in 
SMA liver at a mid/late symptomatic time point (P8: Fig. 7D: *p < 0.05).
Finally, a combination of increased megakaryocytes and clot-like accumulations of platelets in SMA liver and 
heart, prompted us to investigate Annexin-A2, an anticoagulant40 involved in cellular growth41, both of which are 
affected in SMA liver. We found that Annexin-A2 mRNA was significantly reduced in SMA liver at a late symp-
tomatic time point (P11: Fig. 7E: **p < 0.01). Interestingly, Annexin-2 is a binding partner of SMN42 and altered 
in SMA43.
Taken together, these data suggest that low levels of SMN are correlated with an altered molecular signature, 
compatible with the cellular and gross anatomical defects observed in SMA liver.
Antisense Treatment Prolonged Life and Normalised Liver Development in SMA. Morpholino 
antisense oligonucleotide treatment, designed to increase SMN protein levels, delivered at birth, specifically 
rescues a range of neuromuscular pathologies and significantly increases lifespan in SMA mouse models44. In 
Figure 5. Platelets Aggregate into Circulating Clot-like Accumulations in SMA. Representative micrographs 
of H&E and RBCs (Ly76+ DAPI− stain - red) and platelets (CD41+ stain - green) co-stained with DAPI (blue) of 
heart sections obtained at P5 from Taiwanese mice. Red squares show where Immunofluorescence images were 
taken. LV = Left Ventricle. RV = Right Ventricle. Note that the blood accumulation observed in SMA LV is not 
clotted unlike the one in RV. Scale bar for H&E, 500 μ m. Scale bar for Immunofluorescence - left, 50 μ m and - 
right, 10 μ m.
www.nature.com/scientificreports/
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addition it also increases SMN levels in non-neuromuscular tissues such as the intestines45. We used an identical 
treatment regime to test the ability of systemically delivered antisense to ameliorate SMA liver pathology.
At late symptomatic age (P11), the SMA-treated liver exhibits no marked improvement compared to the 
non-treated SMA liver (Fig. 8A). The architecture remains immature, with persistent iron deposits, erythroblas-
tic islands and platelet-producing megakaryocytes (Fig. 8A). However, as the PMO25 treated mice survive for 
extended periods, we examined the treated liver at P21, and found all aspects of liver pathology to be completely 
ameliorated. The architecture of PMO25-treated liver at P21 is indistinguishable from an age-matched control 
liver. There is no evidence of iron deposits, nucleated RBCs or megakaryocytes at P21 (Fig. 8A). These data sug-
gest that the defects in liver development described are specifically due to SMN protein depletion, and can be 
rescued by its restoration. It is intriguing that rescue of SMA liver pathology, was not complete until beyond the 
normal lifespan of a severe SMA mouse.
We confirmed that PMO25 antisense treatment was effective in the liver, by specifically looking for increased 
exon7 inclusion in SMN2 transcripts. We found a significant increase in the amount of full-length (including 
exon7) SMN2 (FL-SMN2) transcript in mid/late symptomatic liver treated with PMO25 antisense at P1 (Fig. 8B: 
**p < 0.01). Surprisingly, we also found that FL-SMN2 was the predominant transcript in control liver.
Discussion
In this study we show that SMN protein is required for normal erythropoiesis and megakaryopoiesis in the 
liver, with SMN depletion leading to significant defects in liver development in SMA. These defects are corrob-
orated by changes in key pathways including: decreased expression of albumin and α-FTP mRNAs indicative 
of a liver-specific developmental defect; decreased expression of Ireb-2 mRNA correlated with dysregulation of 
iron homeostasis; elevated levels of EPO protein correlated with prolonged active erythropoiesis and megakary-
opoiesis, and a decrease in Annexin-A2 mRNA expression, an anti-coagulant and known SMN binding partner, 
which is altered in SMA. Furthermore, we show that antisense treatment increases SMN levels, normalises liver 
pathology and rescues the mice. Finally, we show that Fl-SMN2 is the predominant SMN transcript in control 
Figure 6. Myelopoiesis Does Not Appear to Be Affected in SMA Liver. (A) Representative micrographs 
labelled with the CD11b to show myeloid leukocytes (red), in sections of liver obtained from Taiwanese mice. 
Scale bar, 50 μ m. (B) WBC differential showing the percentage of granulocytes and monocytes in control and 
SMA blood samples obtained from P8 Taiwanese mice. p values were calculated using two-tailed Student’s t-test. 
Error bars, mean ± s.e.m. (n = 4 mice per group).
www.nature.com/scientificreports/
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liver. This adds to the body of evidence suggesting that this antisense treatment regimen offers a promising ther-
apy for patients.
The SMA liver is small but in proportion to lower body mass compared to littermate controls, but exhibits 
structural abnormalities consistent with developmental failure. Here a reduction in global SMN levels results in 
iron accumulation and evidence of liver overload at P5 and P9 in SMA. This suggests that liver development is 
SMN dose-dependent, as deletion of SMN exclusively in the liver results in massive iron overload35. Iron accu-
mulation is a sign of immaturity, which is reinforced by our observation of a failure of hepatic plates to mature 
correctly and prolonged postnatal haematopoiesis. During normal embryonic development, the liver serves as 
the main haematopoietic organ46, peaking at embryonic day 13–1447. Over the first 2–4 postnatal days, this role 
is lost as the bone marrow takes over and this functional shift is reflected in a rapid change in liver architecture to 
a mature pattern. Our results show that the SMA liver fails to undergo this maturational shift, as haematopoietic 
elements are still common at P9. This is further supported by the presence of wide, embryonic pattern, sinusoids48 
filled with normoblasts (nucleated RBC) in SMA.
Complete deletion of the SMN protein specifically targeted to liver resulted in severe impairment of liver 
development and embryonic lethality35. They suggested that functional defects within the liver are likely due 
to an imbalance between haematopoietic elements and maturing hepatocytes. This is consistent with reduction 
of albumin and α-FTP mRNA expression, both of which are almost exclusively expressed in the liver, predom-
inantly by the hepatocytes49, and are decreased following liver-specific knockout of SMN. This is indicative of a 
liver-specific dysfunction associated with marked reduction in the presence of mature, functional hepatocytes. 
The recent availability of induced pluripotent stem cells generated from SMA human fibroblasts50, now provides 
the opportunity to map the developmental changes in hepatocytes in SMA, and potentially identify direct links 
between decrease SMN and defects in liver development in the future.
Figure 7. Molecular Pathways are Modified in SMA Liver. Semi-quantitative RT-PCR analysis of albumin 
(A), α-FTP (B), Ireb-2 (C) and Annexin A2 (E) transcripts in control and SMA livers normalised to Ppia and 
Oaz1. (D) Total erythropoietin protein levels analysed by Western Blot and normalised to the total protein 
(Instant Blue). p values were calculated using two-tailed Student’s t-test. Error bars, mean ± s.e.m. (n ≥ 3 mice 
per group). For uncropped gels/blot see Supplementary Figure 1.
www.nature.com/scientificreports/
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The increase in RBC and platelets in combination with this decreased expression of Annexin-A2 mRNA, likely 
contributes to the clot-like accumulations found in the circulatory system. We speculate that these may be associ-
ated with commonly reported cardiac defects16–23,30,31 and distal necrosis30,31 reported in SMA patients.
The pronounced dark-red phenotype in SMA liver is consistent with the observed increase in RBC as a result 
of on-going erythropoiesis and iron overload, which is necessary for erythroblast maturation51. Therefore, iron 
accumulation and accompanying decrease in Ireb-2 mRNA expression in SMA liver are a likely outcome of persis-
tent active erythropoiesis at later stages of development. Ireb-2, which is a key regulator of vertebrate cellular iron 
Figure 8. Antisense Treatment Prolonged Life and Normalised Liver Development in SMA. (A) Representative 
micrographs of Perl’s, H&E, Ly76, and CD41 staining of liver obtained from treated and non-treated mice at two 
different time-points, P11 and P21. Note the persisting presence of iron deposits (black arrowheads, magnified panel), 
predominant erythroblastic islands, and megakaryocytes in SMA treated liver at P11. This pathology appears to be 
completely ameliorated at P21. Scale bar: Perl’s and H&E staining, 50 μ m; Ly76 and CD41 staining, 100 μ m; Magnified 
panel, 10 μ m. (B) Semi-quantitative RT-PCR analysis of the ratio of FL-SMN2 to Δ7 SMN2 transcripts between 
Control, SMA and antisense treated SMA liver at P11. p values were calculated using two-tailed Student’s t-test. Error 
bars, mean ± s.e.m. (n = 4 mice per group). For uncropped gel see Supplementary Figure 2.
www.nature.com/scientificreports/
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homeostasis37, is significantly reduced in embryonic stem cells with low SMN protein38. Further, motor neurons 
from Ireb-2−/− mice display increased ferritin and impaired mitochondrial function resulting in motor neuron 
degeneration52. We show increased hepatic iron and significant a reduction in Ireb-2 mRNA in SMA liver, which 
taken together with mitochondrial dysfunction in SMA53–55, suggests that iron dysregulation may be important 
in motor neuron degeneration, and a candidate for further study in SMA.
The increase in megakaryocytes and platelets in SMA liver indicate increased megakaryopoiesis. The ele-
vated levels of platelets may be exacerbated by defects in spleen, as in severe SMA mice the spleen is significantly 
reduced in size and atrophic56,57 and contains increased numbers of megakaryocytes57. The spleen is the major site 
for removal of platelets58, and a combination of over production and improper removal could result in elevated 
levels of circulating platelets in SMA.
This in combination with thrombocytosis is predicted to result in clinically-relevant pathologies in SMA 
patients and animal models. Distal necrosis is a common but unexplained phenotypic feature in both mild and 
severe SMA mouse models59–62. Further, though infrequent, digital necrosis is observed in infants with severe 
SMA30,31, and here a treatment composed mainly of anticoagulants resulted in complete resolution of all lesions31. 
Coagulation studies have not revealed abnormalities in SMA type I patients, but these were likely performed on 
platelet-free plasma, focusing more on the coagulation factors rather than platelets themselves. The reports of vas-
cular thrombosis and digital necrosis argue that these are not a result of a perfusion abnormality associated with 
heart defects30. Therefore, thrombosis due to increased levels of circulating platelets and decreased Annexin-A2 
may be an important pathological finding in patients. Intriguingly, recent reports indicate that platelets contain 
surprisingly high amounts of SMN protein32, and Annexin-A2 deficient mice exhibit a hypofibrinolytic phenotype 
with incomplete clearance of thrombi63, suggesting a potential pathway for the promotion of clot formation.
The right atrium of the heart is immediately downstream of the liver, and the presence of clot-like structures 
in the right ventricle is consistent with the liver as the source of platelets. Extending this idea, we predict blood 
clots in the lungs, and previous studies have shown dark reddish discoloration in the lungs of SMA mice upon 
autopsy62, a likely indicator of clotting. The presence of fewer clots in the left ventricle of the heart is consistent 
with a degree of lung-filtering of clots.
We did however find excessive blood pooling in the left ventricle, evidenced by the presence of large numbers 
of RBC. This could be a result of an increase in total blood volume, bradycardia, or an increase in afterload. The 
increased production of RBC and platelets described here will increase blood volume and haematocrit. Such 
an increase in blood viscosity will put additional stress on the heart, which could explain our observation of 
left ventricular blood accumulation and also of cardiomyopathy in SMA patients16,17,30,31 and animal models of 
SMA18,19,24–26. Severe bradycardia is described in many type I patients20,22, which might also be associated with 
blood pooling in the left ventricle. Finally, the reduction in capillary bed density in patient muscle biopsies28 and 
the muscle and spinal cord of SMA mice27,28 would increase afterload leading to blood pooling within the left 
ventricle.
Our observation that myelopoiesis, shown by unchanged myeloid leukocyte levels, is normal in SMA mice, 
further strengthens our argument that SMA liver pathology is not the result of generalised development delay, but 
rather a specific defect. Annexin-A2 knockdown was shown to negatively influence cell cycling41. It is possible that 
decreased SMN acting via Annexin-A2 would affect both erythroid and megakaryocytic lineages, as they arise 
from a common precursor64,65. Cell cycling defects have been implicated in several studies in SMA: ASO-induced 
SMN depletion in adult mice showed that cell signalling pathways were most affected implicating SMN in DNA 
replication and possibly DNA repair66; brain weight and cell number changes in mouse model of severe SMA 
indicated a potential role for SMN in proliferation rather than apoptotic cell death67; and Drosophila loss or gain 
of SMN function disrupts larval growth and germline stem cell proliferation and differentiation68.
We have shown that systemic treatment with PMO25 antisense increases SMN levels and ameliorates histo-
pathological abnormalities in SMA liver. However, unlike the intestines45 where improvement was seen at P11, 
rescue was delayed in PMO25 treated liver. These data suggest that careful planning of potential combinatorial 
approaches to SMA therapy will be required to ensure optimal outcomes.
Most interestingly we show that SMN2 splicing produces more FL-SMN2 than Δ 7SMN2 transcripts in control 
liver at P11, which challenges the accepted.
SMN2 splicing dogma3. These data agree with those in the testis7 and indicate a potential splicing switch that 
requires further investigation.
In conclusion, our data support the view that the reduction in SMN protein levels in severe SMA, results in 
specific and significant defects in liver development, apparent from birth. These defects in erythropoiesis and 
megakaryopoiesis but not myelopoiesis, result in potentially wide-ranging systemic pathology through the for-
mation of circulating blood clots, which have been described in both animal models and SMA patients. Our 
preliminary analysis shows changes in pathways consistent with the developmental defects in liver. We suggest a 
proteomic approach to not only validate our findings but to also further understanding of the molecular cascades 
linking SMN-depletion to these specific pathologies, and thereby develop therapies for all aspects of SMA.
Methods
Animals. Mouse model used in the following experiments is the Taiwanese, also known as Hsieh-Li mouse 
model of severe SMA59. Taiwanese SMA mice on a congenic FVB background were maintained as breeding 
pairs (Smn+/−x Smn−/−; SMN2tg/tg) under standard specific pathogen-free conditions in animal care facilities in 
Edinburgh or University College London.
All experimental protocols were approved by Edinburgh University research and ethics committees and 
carried out in accordance with a license from the United Kingdom Home Office under the Animals (Scientific 
Procedures) Act 1986. Offspring were either homozygous knockouts for Smn, Smn−/−; SMN2tg/0, (SMA) or 
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heterozygous, Smn+/−; SMN2tg/0 (Control). Mice were retrospectively genotyped following standard Polymerase 
Chain Reaction (PCR) protocols69. Day of birth was defined as P1.
Tissue Processing, H&E and Perl’s Staining. All tissue used in these experiments was harvested from 
mice sacrificed at desired age by intraperitoneal injection of sodium pentobarbital, in accordance with UK the 
guidance and rules for the use of animals in research and were carried out at the University of Edinburgh. Whole 
liver and heart were rapidly dissected and fixed for 4 h in 4% paraformaldehyde (PFA). Sequentially, one part 
of the liver and whole heart were then cryoprotected in 30% sucrose for subsequent OCT embedding, and the 
other liver part submerged in 70% ethanol to be processed in wax. After sectioning (5 μ m), wax embedded liver 
and OCT embedded heart were stained in Haematoxylin and Eosin (H&E) or for iron (Prussian blue reaction – 
Mallory’s method) co-labeled with 0.1% Nuclear fast red solution (Sigma-Aldrich N3020) following a standard 
protocol.
White Blood Cell Differential. Under terminal anaesthesia induced by isoflurane, the thoracic cavity 
of Taiwanese SMA mice and their littermates was surgically opened. Using a 30gauge 0.3 ml insulin syringe a 
blood withdrawn performed by cardiac puncture into the left ventricle. One drop of blood was used to make 
a blood smear and the remaining placed in a tube with 0.5 M EDTA as an anticoagulant (1:20 anticoagulant to 
blood ratio) and inverted to ensure proper mix. Mice were culled by exsanguination (non-Schedule 1 procedure). 
Samples were placed on ice and immediately taken for WBC differential analysis at the Veterinary Pathology Unit, 
University of Edinburgh.
Immunohistochemistry. Cryosections were cut at a thickness of 7 μ m and stained with rat monoclonal 
anti-Ly76 primary antibody (Abcam ab91113, 1:100) or rat monoclonal anti-CD41 (AbD Serotec MCA2245GA, 
1:100) or rabbit monoclonal anti-CD11b (Abcam ab133357, 1:100). Stains were visualised with Alexa Fluor 
488 goat anti-Rat IgG (H + L) (Life Technologies A-11006, 1:200) and Cy3 goat anti-Rat IgG (H + L) (Life 
Technologies A-10522, 1:200) or Cy3 goat anti-Rabbit IgG (H + L) (Life Technologies A-10520, 1:250). For triple 
stain (Ly76 co-label with CD41 and DAPI) the staining was carried out subsequently as the primary antibodies 
were raised in the same host with Ly76 staining performed first. All slides were mounted in Vectashield mount-
ing media containing DAPI (Vector Laboratories H-1200). All sections were imaged using a Nikon eclipse e400 
microscope (× 10 objective) and its images captured using QICAM Fast 1394 camera and Improvision Velocity 
4 image capture software.
Ly76 Density Imaging and Quantification. The density of Ly76 positive cells in liver was calculated from 
3 sections per slide from a minimum of 6 non-consecutive slides for each mouse. Tissues that were poorly stained 
and/or damaged due to sectioning or where < 50% of the area was not occupied by nuclei, due to the presence of 
large blood vessels were excluded from the analysis. One image approximately in the middle of the whole tissue 
per section was captured at x100 magnification, and all images were captured at the same exposure. All images 
sere enhanced in Abode Photoshop (CS4) for contrast and brightness. Using Image J (NIH) the enhanced images 
were converted to binary where all Ly76 positive cells were assigned black and background white. This allowed 
calculation of a ratio of black to total white pixels producing a value for relative number of Ly76 positive cells per 
field of view, expressed as percentage of field of view occupied by relative number of Ly76 positive cells. To elimi-
nate bias, quantification P1 and P9 was carried out on blinded slides.
Erythrocyte Precursor Cell Imaging and Quantification. For analysis of Ly76 + DAPI positive cells, 
at least 24 images per liver were analysed. All sections were captured at x200 magnification, enhanced in Abode 
Photoshop for contrast and brightness prior to merging Ly76-green and DAPI-blue channels. Cells that were 
positive for Ly76 and DAPI were classified as erythrocyte precursor cells and counted. For cell counting, a ran-
dom systematic sampling method was used. The random element was created by the unknown orientation of 
the tissue during its embedding in the OCT. Systematic because imaging of all the livers followed the same rules: 
(a) four, non-overlapping, images were taken per section starting from the top, left of each section, (b) poorly 
stained and/or damaged sections were not imaged, (c) images where < 50% of the area was not occupied by 
nuclei, due to the presence of large blood vessels were not imaged, (d) at least six sections per mouse were imaged, 
and (e) all imaged sections were at least 30 μ m apart. To eliminate bias, the quantification of P1 and P9 was carried 
out on blinded slides.
AON Treatment of SMA Mice. All AON experimental procedures were performed on mice bred at 
University College London.
In this study we used a 25-mer morpholino antisense oligomer (PMO25), which targets the ISS-N170, increas-
ing the inclusion of exon7 in SMN2 transcripts and consequently elevating the total full-length SMN protein 
levels36,44,45,71–73.
PMO25 was synthesised by Gene Tools (Philomath, OR) for research use only. SMA mice were injected with a 
single subcutaneous dose of 40 μ g/g PMO25 at birth. Subcutaneous administrations were injected into the upper 
part of the back using a 10 μ l glass capillary (Drummond Scientific Company #5-000-1001-X10). All treated SMA 
mice are henceforth referred to as SMA + PMO25.
Semi-Quantitative Reverse Transcription PCR (RT-PCR). Extraction of total RNA from liver samples 
was achieved using RNeasy Mini Kit (Qiagen 74104). RNA concentration was determined by a Nanodrop 2000 
spectrophotometer. Total RNA (1 μ g) was used for first-strand cDNA synthesis, using SuperScript II Reverse 
Transcriptase kit (Life Technologies 18064014). The following murine primers were designed for the RT-PCR anal-
ysis: Albumin (forward, 5′ -CCTGCCACCATTTGAAAGGC-3′ ; reverse, 5′ -GTGTCATGCTCCACCTCACT-3′ ), 
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:34635 | DOI: 10.1038/srep34635
α-FTP (forward, 5′ -CTGCTACATTTCGCTGCGTC-3′ ; reverse, 5′ -TGGTTGTTGCCTGGAGGTTT-3′ ), 
Annexin A2 (forward, 5′ -CAACCAGGAGCTGCAAGAGA-3′ ; reverse, 5′ -GTGCCTTCTGGTAGTCACCC-3′ ), 
Ireb-2 (forward, 5′ -AGCTCCAGACTCCGTGC-3′ ; reverse, 5′ -GGCAGCCCAATCTCTTGAAT-3′ ), Ppia74, 
and Oaz174. For SMN2 transcript analysis human SMN-specific primers were used44. Their specificity was 
tested on a wild type mouse showing no cross-reactivity with the murine Smn transcripts (data not shown). 
Semi-quantification of band intensity was analysed by ImageJ.
Quantitative Fluorescent Western Blot Analysis. Western blot analysis was performed as previ-
ously described75. Briefly, liver was manually homogenised and all protein extracted in RIPA buffer (Thermo 
Scientific™ 89900) containing 1% Halt™ Protease Inhibitor Cocktail (Thermo Scientific™ 78430). Protein con-
centration was determined by BCA assay (Thermo Scientific™ 23235). Each lane was loaded with 15 μ g of pro-
tein. Extracted protein was separated by electrophoresis on precast NuPAGE™ Novex™ 4–12% Bis-Tris protein 
gels (Invitrogen NP0336PK2) and then transferred to nitrocellulose membrane (Novex™ IB23002) using the iBlot 
7 minute semi-dry blotting system. Membrane was blocked in Odyssey blocking buffer (LI-COR 927-40000) for 
90 minutes at room temperature. Primary antibody against Erythropoietin (Abcam ab129452, 1:200) was diluted 
in blocking solution and left overnight at 4 °C. Following 6 × 10 minute washes in 0.1M PBS, Alexa Fluor 680 
donkey anti-Rabbit Ig (H + L) (Abcam ab186692, 1:10000) was added and membrane incubated for 90 minutes 
at room temperature. Blots were washed 6 × 10 minutes in 0.1 M PBS and subsequently imaged using an Odyssey 
Infrared Imaging System and quantified using Image Studio Software (Image StudioTM Lite, Lincoln, NE). Due to 
alteration in the expression levels of many standard loading control proteins in SMA tissues, total protein levels 
were used as a loading control76. Total protein levels were determined by incubation of control gel in Instant Blue 
(Sigma-Aldrich ISB1L). Erythropoietin band intensities were then normalised to a loading control to determine 
final relative protein expression.
Statistics. All experimental groups consisted of a minimum of 3 different animals, which we have previ-
ously shown to be sufficient to attain statistical significance27,28. Data was collected in Microsoft Excel software 
(Microsoft Corporation, Redmond, WA). Graphs were generated and statistical analysis performed in GraphPad 
Prism software (GraphPad Sofware Inc., La Jolla, CA). Bar charts are shown as mean ± SEM. For statistical anal-
ysis, unpaired two-tailed Student’s t-test has been used and P < 0.05 was considered statistically significant for all 
analyses.
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